Innovent and Etana’s Bevagen (biosimilar, bevacizumab) Receive BPOM’s Approval for the Treatment of Cancers in Indonesia
Shots:
- BPOM has approved Bevagen (biosimilar, bevacizumab) for 5 indications incl. m-CRC, locally recurrent or m-TNBC, NSCLC, epithelial ovarian, fallopian tube, primary peritoneal cancer & CC. Each Bevagen single-use vial has a 4mL (25mg/mL) vial containing 100mg of bevacizumab
- Based on product quality & manufacturing procedures, the approval in Indonesia certified Bevagen's compliance with the drug safety & efficacy requirements established by the Indonesian government
- Following the license agreement with Innovent, Etana will commercialize Bevagen in Indonesia & can improve access to high-quality & affordable biosimilar drugs to satisfy the needs of cancer patients. Bevagen will be 1st locally produced and commercialized Chinese Ab therapy in Southeast Asia
Ref: PR Newswire | Image: Innovent
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
